# A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

> **NCT00796445** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 1351 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** GSK 2132231A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00796445
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12-01
- **Primary completion:** 2016-01-27
- **Final completion:** 2016-01-27
- **Target enrollment:** 1351 (ACTUAL)
- **Why stopped:** The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796445, "A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00796445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*